Novelion Therapeutics Inc. announced that effective on November 29, 2016, Dr. Jorge Plutzky, Mr. Sandford Smith, Mr. Donald Stern, Ms. Mary Szela
and Ms. Anne VanLent, each of whom served on the board of directors of Aegerion prior to the Merger, and Mr. Kevin Kotler were appointed to the board of directors of the company. On November 29, 2016, Ms. Szela was appointed Chief Executive Officer of the company. In this role, Ms. Szela
will serve as Novelion's Principal Executive Officer. Ms. Szela succeeds Dr. Cox, who has served as Interim Chief Executive Officer of Novelion since October 23, 2014. Mr. Gregory Perry, 56, was appointed Chief Financial and Administrative Officer of Novelion, effective November 29, 2016 and will serve as Principal Financial Officer of Novelion. Mr. Perry served as Aegerion's Chief Financial and Administrative Officer prior to the Merger and as Chief Financial Officer of Eleven Biotherapeutics Inc. from January 2014 until July 2015, when he joined Aegerion as Chief Financial Officer. Ms. Barbara Chan, 53, was appointed President and Chief Accounting Officer of Aegerion, effective December 1, 2016. Ms. Chan will serve as the Principal Accounting Officer of Novelion.